Definium Therapeutics Inc. (DFTX) — NEW YORK, July 20, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 30,330 common shares of the Company (the "Options") with effective grant dates of July 20, 2026. The
Source: Business Wire — read the full announcement there.
Browse more sector announcements in our press release archive.